Compare GERN & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | TRNS |
|---|---|---|
| Founded | 1990 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 799.0M |
| IPO Year | 1996 | 1995 |
| Metric | GERN | TRNS |
|---|---|---|
| Price | $1.52 | $92.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.17 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 10.8M | 125.0K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $1,065,000.00 | ★ $331,877,000.00 |
| Revenue This Year | $26.91 | $21.75 |
| Revenue Next Year | $43.75 | $7.55 |
| P/E Ratio | ★ N/A | $653.64 |
| Revenue Growth | N/A | ★ 19.20 |
| 52 Week Low | $1.04 | $50.23 |
| 52 Week High | $2.01 | $100.00 |
| Indicator | GERN | TRNS |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 53.45 |
| Support Level | $1.42 | $85.90 |
| Resistance Level | $1.68 | $94.58 |
| Average True Range (ATR) | 0.10 | 4.55 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 58.82 | 56.62 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.